Unlock stock picks and a broker-level newsfeed that powers Wall Street.
OTC Markets OTCQB - Delayed Quote USD

Numinus Wellness Inc. (NUMIF)

Compare
0.0190
0.0000
(0.00%)
At close: April 2 at 4:00:00 PM EDT
Loading Chart for NUMIF
  • Previous Close 0.0000
  • Open 0.0180
  • Bid 0.0180 x --
  • Ask 0.0200 x --
  • Day's Range 0.0153 - 0.0180
  • 52 Week Range 0.0090 - 0.0900
  • Volume 80,879
  • Avg. Volume 100,550
  • Market Cap (intraday) 11.213M
  • Beta (5Y Monthly) 2.45
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0600
  • Earnings Date Apr 3, 2025 - Apr 13, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Numinus Wellness Inc. provides psychedelic-assisted psychotherapy products and services in Canada and the United States. The company operates through Clinical Research Operations, Canadian Clinic Network, and U.S Clinic Network segments. The Clinical Research Operations segment offers clinical research management services to academic institutions and biotechnology companies. The Canadian Clinic Network segment provides clinical services, including traditional therapy and counseling, ketamine-assisted therapies for depression, psychedelic-assisted therapies, mindfulness programs, and virtual psychotherapy services, as well as neurological care services. The US clinic network segment offers psychedelic-assisted therapies, transcranial magnetic stimulation, and psychiatric and medical model management services. The company also offers laboratory services, such as the cultivation, production, and extraction of natural Psilocybe and other psychoactive fungi species, the development of proprietary processes and products, methods for controlled psychedelics and development of a pipeline for product development, and protocol development and safety and efficacy studies; lab testing services; and psychedelic-assisted therapy training services. The company was incorporated in 1964 and is headquartered in Vancouver, Canada.

www.numinus.com

--

Full Time Employees

August 31

Fiscal Year Ends

Recent News: NUMIF

View More

Performance Overview: NUMIF

Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

NUMIF
24.00%
S&P/TSX Composite index (^GSPTSE)
2.79%

1-Year Return

NUMIF
74.67%
S&P/TSX Composite index (^GSPTSE)
14.64%

3-Year Return

NUMIF
95.94%
S&P/TSX Composite index (^GSPTSE)
15.28%

5-Year Return

NUMIF
98.19%
S&P/TSX Composite index (^GSPTSE)
93.22%

Compare To: NUMIF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NUMIF

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    11.21M

  • Enterprise Value

    13.57M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.34

  • Price/Book (mrq)

    1.89

  • Enterprise Value/Revenue

    0.86

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -113.22%

  • Return on Assets (ttm)

    -51.49%

  • Return on Equity (ttm)

    -187.91%

  • Revenue (ttm)

    22.48M

  • Net Income Avi to Common (ttm)

    -25.51M

  • Diluted EPS (ttm)

    -0.0600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.7M

  • Total Debt/Equity (mrq)

    152.76%

  • Levered Free Cash Flow (ttm)

    -8.22M

Research Analysis: NUMIF

View More

Company Insights: NUMIF

Research Reports: NUMIF

View More

People Also Watch